Enzytec

Sem categoria

Enzytec obtains Sanitary Permit for Importation and Distribution of Health Products according to RDC 16/2013 ANVISA

ENZYTEC NEWS Enzytec obtains Sanitary Permit for Importation and Distribution of Health Products according to RDC 16/2013 ANVISA In April 2022, Enzytec Biotecnologia obtained the Sanitary Permit for Importation and Distribution of Health Products. With long experience in regulatory consulting and technology development, in this new phase the company will also act as a distributor […]

Enzytec obtains Sanitary Permit for Importation and Distribution of Health Products according to RDC 16/2013 ANVISA Read More »

RDC 675/22

ENZYTEC NEWS RDC 675/22 The new RDC 675 came into force in March 2022, which deals with the adequacy of drugs registered until June 2, 2003 and which did not present evidence of therapeutic equivalence at the time of registration. According to ANVISA, RDC 675/22, which revokes RDCs 134/2003, 210/2004, 37/2011 and 98/2016, comes with

RDC 675/22 Read More »

RDC 665/22

ENZYTEC NEWS RDC 665/22 The new RDC 665 came into force in May 2022, which provides for Good Manufacturing Practices for Medical Products and In Vitro Diagnostic Products, applying to manufacturers, importers and distributors who sell in Brazil. For you who are an entrepreneur in the health market or looking for ways to enter the

RDC 665/22 Read More »

Enzytec develops In Vitro diagnostic reagent for canine Cystatin C detection

ENZYTEC NEWS Enzytec develops In Vitro diagnostic reagent for canine Cystatin C detection In partnership with the UFMG Veterinary School, the CEO of Enzytec, Dr. Márcio Lacerda, along with Prof. Dr. Fabiola Paes-Leme developed a reagent capable of measuring canine Cystatin C, an early marker in dogs prone to acute kidney injury. To assess the

Enzytec develops In Vitro diagnostic reagent for canine Cystatin C detection Read More »

Enzytec supports Biotechtown in obtaining ANVISA’s Good Manufacturing Practices for In Vitro Diagnostics

ENZYTEC NEWS Enzytec supports Biotechtown in obtaining ANVISA’s Good Manufacturing Practices for In Vitro Diagnostics Enzytec with its Regulatory Affairs team provided consultancy for the adequacy of the Biotechtown manufacturing unit. At the time, the demand was to make the CMO (Contract Manufacturing Organization) comply with the Good Practices of Control and Manufacturing according to

Enzytec supports Biotechtown in obtaining ANVISA’s Good Manufacturing Practices for In Vitro Diagnostics Read More »

Enzytec supports Medmax in obtaining ANVISA’s Good Manufacturing Practices for In Vitro Diagnosis

ENZYTEC NEWS Enzytec supports Medmax in obtaining ANVISA’s Good Manufacturing Practices for In Vitro Diagnosis Enzytec, with its Regulatory Affairs team, provided consulting services to MEDMAX, a company that produces equipment and reagents for In Vitro diagnostics, with the aim of adapting its manufacturing unit to comply with Good Control and Manufacturing Practices according to

Enzytec supports Medmax in obtaining ANVISA’s Good Manufacturing Practices for In Vitro Diagnosis Read More »

Enzytec CEO Develops In Vitro Diagnostic Reagent for Early Renal Marker Detection in Dogs

ENZYTEC NEWS Enzytec CEO Develops In Vitro Diagnostic Reagent for Early Renal Marker Detection in Dogs In partnership with the UFMG Veterinary School, the CEO of Enzytec, Dr. Márcio Lacerda, along with Prof. Dr. Fabiola Paes-Leme developed a reagent capable of interacting with the early marker of acute kidney injury in dogs, the enzyme N-acetyl-β-D-glucosaminidase

Enzytec CEO Develops In Vitro Diagnostic Reagent for Early Renal Marker Detection in Dogs Read More »